Cargando…
Pooled Analysis of Clinical Outcome of Patients with Chemorefractory Metastatic Colorectal Cancer Treated within Phase I/II Clinical Studies Based on Individual Biomarkers of Susceptibility: A Single-Institution Experience
BACKGROUND: Patients with metastatic colorectal cancer (mCRC) refractory to standard therapies have a poor prognosis. In this setting, recruitment into clinical trials is warranted, and studies driven by selection according to individual tumor molecular characteristics are expected to provide added...
Autores principales: | Sartore-Bianchi, Andrea, Amatu, Alessio, Bonazzina, Erica, Stabile, Stefano, Giannetta, Laura, Cerea, Giulio, Schiavetto, Ilaria, Bencardino, Katia, Funaioli, Chiara, Ricotta, Riccardo, Cipani, Tiziana, Schirru, Michele, Gambi, Valentina, Palmeri, Laura, Carlo-Stella, Giulia, Rusconi, Francesca, Di Bella, Sara, Burrafato, Giovanni, Cassingena, Andrea, Valtorta, Emanuele, Lauricella, Calogero, Pazzi, Federica, Gambaro, Alessandra, Ghezzi, Silvia, Marrapese, Giovanna, Tarenzi, Emiliana, Veronese, Silvio, Truini, Mauro, Vanzulli, Angelo, Siena, Salvatore |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5524857/ https://www.ncbi.nlm.nih.gov/pubmed/28669023 http://dx.doi.org/10.1007/s11523-017-0505-6 |
Ejemplares similares
-
Clonal evolution and KRAS-MET coamplification during secondary resistance to EGFR-targeted therapy in metastatic colorectal cancer
por: Sartore-Bianchi, Andrea, et al.
Publicado: (2016) -
Novel CAD-ALK gene rearrangement is drugable by entrectinib in colorectal cancer
por: Amatu, Alessio, et al.
Publicado: (2015) -
The Evolutionary Landscape of Treatment for BRAF(V600E) Mutant Metastatic Colorectal Cancer
por: Mauri, Gianluca, et al.
Publicado: (2021) -
Liquid Biopsy for Prognosis and Treatment in Metastatic Colorectal Cancer: Circulating Tumor Cells vs Circulating Tumor DNA
por: Patelli, Giorgio, et al.
Publicado: (2021) -
Case Report: MAP2K1 K57N mutation is associated with primary resistance to anti-EGFR monoclonal antibodies in metastatic colorectal cancer
por: Mauri, Gianluca, et al.
Publicado: (2022)